YM BIOSCIENCES
YM BioSciences is a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development. YM has proven regulatory and clinical trial expertise and a diversified business model designed to reduce risk while advancing clinical products toward international approval, marketing and commercialization.
YM BIOSCIENCES
Industry:
Biotechnology Pharmaceutical
Founded:
1994-01-01
Address:
Toronto, Ontario, Canada
Country:
Canada
Website Url:
http://www.ymbiosciences.com
Total Employee:
11+
Status:
Closed
Contact:
(905) 629-9761
Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS Zoom Video Conferencing Zoom Proofpoint NetNames DNS
Similar Organizations
EpiVax
EpiVax is an immunology company developing comprehensive analytical capabilities in the field of computational immunology.
Leadiant Biosciences
Leadiant Biosciences is a pharmaceutical company dedicated to the development, registration and commercialization of effective therapies.
Current Advisors List
Board_member
Board_member
Current Employees Featured
Tarrnie Williams Founder & Director @ YM BioSciences
Founder & Director
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2009-10-06 | Cytopia | Cytopia acquired by YM BioSciences | N/A |
| 2006-04-01 | Eximias Pharmaceutical Corporation | Eximias Pharmaceutical Corporation acquired by YM BioSciences | 29 M USD |
Official Site Inspections
http://www.ymbiosciences.com
- Host name: 64-79-124-206.static.wiline.com
- IP address: 64.79.124.206
- Location: Belmont United States
- Latitude: 37.5136
- Longitude: -122.2916
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94002
More informations about "YM BioSciences"
YM BioSciences - Crunchbase Company Profile
Organization. YM BioSciences . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. YM …See details»
YM Biosciences - PitchBook
YM Biosciences General Information Description. Developer of life sciences products. The company licenses and commercializes drug products and technologies primarily for the …See details»
YM Biosciences - Wikipedia
YM BioSciences' principal medicine of interest was a monoclonal antibody – Nimotuzumab – targeting the epidermal growth factor receptor. YM BioSciences received Orphan Drug Designation from the FDA for Nimotuzumab in 2004 and received a number of single-patient IND clearances starting in 2005. After receiving approval from the Office of Foreign Asset Control in March 200, the first patient was treated at Doernbecher Children's Hospital of Oregon Health an…See details»
YM BioSciences - Ownership and Business Overview - Mergr
Dec 12, 2012 YM BioSciences Inc. is a drug development company primarily focused on advancing CYT387, an orally administered inhibitor of both the JAK1 and JAK2 kinases, which …See details»
Cuban Life Sciences YM BioSciences Inc - cresswelladvisors.com
YM BioSciences was incorporated in 1994 as one of Canada's first "receptor companies" designed to advance the novel biotechnological basic research from academic institutes …See details»
YM BioSciences - Funding, Financials, Valuation & Investors
Oct 6, 2009 Organization. YM BioSciences . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Funding. YM BioSciences is …See details»
YM BioSciences Inc. - Mississauga, Canada - bionity.com
Aug 12, 2010 YM BioSciences Inc. is a company that identifies, develops and commercializes differentiated products principally in the area of oncology for patients worldwide.See details»
YM BioSciences - Products, Competitors, Financials, Employees ...
YM BioSciences is a life sciences product development company advancing a diverse portfolio of hematology and cancer-related products at various stages of development. In February 2013, …See details»
Company YM BioSciences Inc. - MarketScreener.com
YM BioSciences Inc.: Company profile, business summary, shareholders, managers, financial ratings, industry, sector and market information | Toronto S.E.: YM ...See details»
YM BioSciences - Crunchbase
YM BioSciences is a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-relatedSee details»
Ym Biosciences Inc Profile - Stockopedia
Executive Summary. YM BioSciences Inc. is a cancer product development company. Its lead drug, tesmilifene, is a small molecule chemopotentiator currently undergoing a 700-patient …See details»
YM BioSciences - Company Profile - Tracxn
Oct 20, 2024 YM BioSciences was focussed on developing cancer-related drugs. Its lead candidate CYT387, which it got from the acquisition of Cytopia was a JAK inhibitor which was …See details»
YM BioSciences USA - PitchBook
Oct 4, 2000 YM BioSciences USA General Information Description. Developer of products for the treatment of cancer, cancer-related disorders and infectious diseases. The company's …See details»
Working at YM BioSciences - Glassdoor
The "YM" in BioSciences might stand for "young and modern" as once the letters of YM magazine did. The firm was founded in 1994 to develop a variety of new anti-cancer technologies by …See details»
YM BioSciences - Tech Stack, Apps, Patents & Trademarks
YM BioSciences is a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-relatedSee details»
YM BioSciences shares up 55% on drug approval | CBC News
Aug 10, 2009 Shares of YM BioSciences Inc. leaped 55 per cent Monday after the company said it has received a U.S. licence to further develop its nimotuzumab treatment for patients with …See details»
What is YM BioSciences? Company Culture, Mission, Values
See what employees say it's like to work at YM BioSciences. Salaries, reviews, and more - all posted by employees working at YM BioSciences.See details»
YM BioSciences completes merger with Cytopia - bionity.com
CYT387 is an oral JAK1/2 inhibitor, originating from the seminal discovery of JAK1 and JAK2 by Dr. Andrew Wilks, the founder of Cytopia. A Phase I/II myelofibrosis study commenced in …See details»
北京茂扬生物技术有限公司
北京茂扬生物技术有限公司成立于2009年，是一家以生物技术外包服务为主营业务的民营科技企业。作为国内领先的专业化服务公司，主要为国内外新药研究和基础研究两大领域客户提供以免 …See details»
联系方式-北京茂扬生物技术有限公司 - mybiosciences.com
版权所有@ 2007 北京茂扬生物技术有限公司 ICP备案号京ICP备10026951号. 电话:010－63812611 手机:13717571087 邮件:maoyangbiotech@163.com. 地址：北京市丰台区丰 …See details»